Skip to content

The clinical safety of proximal gastrectomy for advanced gastric cancer with long diameter =4cm

The clinical safety of proximal gastrectomy for advanced gastric cancer with long diameter = 4cm

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025554
Enrollment
Unknown
Registered
2019-09-01
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Total gastrectomy:Total gastrectomy
Proximal gastrectomy :Proximal gastrectomy

Sponsors

Jiangsu Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years, male or female; 2. Be diagnosed as adenocarcinoma by endoscopic biopsy; 3. The tumor is located in the the upper third of the stomach(including the esophagogastric junction), the long diameter =90g / L; white blood cell count (WBC)>= normal limit; neutrophil absolute value (ANC) >=1.5 x 10^9 / L; platelet count >= 100x 10^9 / L; Renal function: Cr= 55 ml / min; Liver function: total bilirubin <= ULN × 1.5; ALT and AST <= ULN × 2.5; Coagulation function: international normalized ratio of prothrombin time <= ULN × 1.5, and partial thromboplastin time is within the normal range; Pre-meal blood glucose <= 7mmol/L; 7. Effective contraceptive measures are required during the study period of women of childbearing age; 8. Patients or their legal representatives voluntarily participate in and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Severe mental illness; 3. Intraoperative exploration revealed that the tumor was not suitable for proximal gastrectomy or could not achieve the required lymph node dissection; 4. The general classification of the tumor is diffuse infiltration (Borrmanns type IV); 5. Preoperative or intraoperative detection of distant organ metastasis or extensive intra-abdominal metastasis; 6. Combined with simultaneous or metachronous other organ tumors; 7. Filed to complete radical surgery, palliative resection of the tumor; 8. Previous history of gastrointestinal surgery; 9. Previous history of neoadjuvant chemoradiation; 10. A serious concomitant disease that may have a survival period of < 5 years; 11. Cases that the investigator considered unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
3-year RFS;

Secondary

MeasureTime frame
Postoperative nutritional status;

Countries

China

Contacts

Public ContactHuanqiu Chen

Jiangsu Cancer Hospital

drchenhuanqiu@sina.com+86 13705161013

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026